Questions Loom Over Androgen-Targeting Strategies in Metastatic Prostate Cancer
March 22nd 2016Targeting androgen receptor signaling with recently approved agents has improved outcomes for men with metastatic castration-resistant prostate cancer but significant questions linger about how to tackle resistance to the therapies.
Read More
Pancreatic Cancer Vaccine Makes Progress in Two Late-Stage Trials
March 10th 2016The novel therapeutic vaccine algenpantucel-L, which is genetically engineered from human cell lines, is being evaluated in two phase III trials in patients with resected pancreatic cancer (IMPRESS) and borderline resectable or locally advanced unresectable pancreatic cancer (PILLAR).
Read More
Biomarker-Directed Galeterone Explored in Prostate Cancer Trial
February 24th 2016Galeterone is being explored in the ARMOR 3-SV study, in which men with progressive metastatic disease who have received prior androgen deprivation therapy are randomized to receive either galeterone or enzalutamide.
Read More
FDA Agrees to Review Supplemental NDA for Enzalutamide in Metastatic Prostate Cancer
February 23rd 2016The FDA has accepted, for review, a supplemental new drug application for enzalutamide (Xtandi) capsules in patients with metastatic castration-resistant prostate cancer that includes findings from the head-to-head studies, TERRAIN and STRIVE.
Read More
Durvalumab/Tremelimumab Combo Explored in Lung Cancer Trial
February 5th 2016With the approval of a dual checkpoint blockade treatment in melanoma, researchers hope to have similar success in a phase III trial that combines a PD-L1 inhibitor and CTLA-4 antibody in patients with non–small cell lung cancer.
Read More
In a Crowded Field, High-Intensity Focused Ultrasound Stakes a Claim
February 2nd 2016The landscape for the patient with localized prostate cancer is filled with both new and exciting treatments. With better methods to screen, improved imaging scans to determine physical location and extent of cancer, and even active surveillance, there are many options to consider.
Read More
Genomic Classifier Refines Risk Calculation After Prostatectomy
February 1st 2016Using a genomic classifier that identifies men who are at highest risk for developing metastasis after prostatectomy and salvage radiation therapy can help clinicians distinguish which patients would benefit from more aggressive follow-up therapy, according to recent research.
Read More
Ublituximab Is Combined With Ibrutinib in High-Risk CLL Study
January 13th 2016Researchers are combining the novel CD20-targeting agent ublituximab (TG-1101) with ibrutinib to determine whether the regimen can improve outcomes in CLL, particularly for patients whose disease has high-risk features.
Read More
Prostate Cancer Guidelines Lack Molecular Test Recommendations
December 15th 2015When compared with the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, the corresponding prostate cancer guidelines fall short in one distinct characteristic—the lack of a molecular test in tissue-based platforms at this point in time.
Read More
Promising Subgroup Data Leads to Phase III Immunotherapy Study for GBM
November 21st 2015Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.
Read More
Physician Dispensing of Abiraterone and Enzalutamide for mCRPC Gains Appeal
November 7th 2015With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.
Read More
Early Docetaxel, ADT Combo Increases Survival in Advanced Prostate Cancer
August 10th 2015Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.
Read More